455 reports of this reaction
2.0% of all CARBOXYMETHYLCELLULOSE SODIUM reports
#9 most reported adverse reaction
CATARACT is the #9 most commonly reported adverse reaction for CARBOXYMETHYLCELLULOSE SODIUM, manufactured by Allergan, Inc.. There are 455 FDA adverse event reports linking CARBOXYMETHYLCELLULOSE SODIUM to CATARACT. This represents approximately 2.0% of all 22,264 adverse event reports for this drug.
Patients taking CARBOXYMETHYLCELLULOSE SODIUM who experience cataract should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CATARACT is a less commonly reported adverse event for CARBOXYMETHYLCELLULOSE SODIUM, but still significant enough to appear in the safety profile.
In addition to cataract, the following adverse reactions have been reported for CARBOXYMETHYLCELLULOSE SODIUM:
The following drugs have also been linked to cataract in FDA adverse event reports:
CATARACT has been reported as an adverse event in 455 FDA reports for CARBOXYMETHYLCELLULOSE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CATARACT accounts for approximately 2.0% of all adverse event reports for CARBOXYMETHYLCELLULOSE SODIUM, making it a notable side effect.
If you experience cataract while taking CARBOXYMETHYLCELLULOSE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.